Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Giving to Research
    • How You Can Help
    • Events

Funded Grants

Back to results

Selectively Targeting ERK Signaling to Treat Fragile X Syndrome and Autism

Project Overview

Autism is one of the most prevalent neurodevelopmental disorders in Canada. It has a profound impact on the health, wellness and socioeconomic wellbeing of the patients and their families. The etiology of autism is multifaceted but Extracellular signal-Regulated Kinase (ERK) pathway in the brain is a critical convergent node in the development of autism and Fragile X Syndrome (FXS). FXS is caused by mutations in the fmr1 gene and is the leading monogenic cause of autism and intellectual disability. So far, pharmacological treatments in animal models and clinical trials have used drugs that non-selectively inhibit ERK signalling and mainly affect other pathways. Thus, it is critical to determine whether directly and selectively targeting ERK pathway is beneficial in these diseases. Furthermore, a translational biomarker that tracks treatment response is urgently needed.

Recently, a selective ERK signalling inhibitor, PD325901(PD), has been found to penetrate blood-brain barrier and has strong safety data in clinical trials for neurofibromatosis type-1. We hypothesize that PD will exert beneficial effects in mouse models of FXS and idiopathic autism. We have collected strong preliminary data on acute and sub-chronic treatment with PD. Our results indicated that the treatment dose-dependently reversed certain core disease-modelling deficits in the behavioural domain in mouse models of FXS and idiopathic autism without side effects. In addition, the treatment reduced abnormally increased power of high gamma band in EEG in both models. Here, we will determine: 1. the efficacy time window, optimal dosage, and potential side effects of chronic inhibitor treatment; 2. whether EEG signal tracks behavioural improvement as a potential non-invasive biomarker. The proposed study will provide necessary groundwork and directly translatable insights toward applying PD in clinical trials for FXS and autism.

Principal Investigator

Ning Cheng , University of Calgary

Partners and Donors

Kids Brain Health Network

Project Ongoing

Selectively Targeting ERK Signaling to Treat Fragile X Syndrome and Autism

  • Program Type

    Capacity building grants

  • Area of research

    Neurodevelopment

  • Competition

    KBHN Early Career Investigator & Mentorship Awards

  • Province

    Alberta

  • Start Date

    2022

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co